Burney Co. Has $11.59 Million Stock Position in AbbVie Inc. $ABBV

Burney Co. reduced its position in shares of AbbVie Inc. (NYSE:ABBV) by 3.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 62,417 shares of the company’s stock after selling 1,914 shares during the period. Burney Co.’s holdings in AbbVie were worth $11,586,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. Torray Investment Partners LLC boosted its holdings in shares of AbbVie by 267.7% during the 2nd quarter. Torray Investment Partners LLC now owns 95,042 shares of the company’s stock worth $17,642,000 after buying an additional 69,195 shares during the period. State of Michigan Retirement System boosted its holdings in AbbVie by 0.3% in the 2nd quarter. State of Michigan Retirement System now owns 480,308 shares of the company’s stock valued at $89,155,000 after purchasing an additional 1,400 shares during the period. Carson Advisory Inc. boosted its holdings in AbbVie by 10.4% in the 2nd quarter. Carson Advisory Inc. now owns 2,709 shares of the company’s stock valued at $503,000 after purchasing an additional 256 shares during the period. iA Global Asset Management Inc. boosted its holdings in AbbVie by 18.6% in the 2nd quarter. iA Global Asset Management Inc. now owns 5,125 shares of the company’s stock valued at $951,000 after purchasing an additional 805 shares during the period. Finally, Gilbert & Cook Inc. boosted its holdings in AbbVie by 3.4% in the 2nd quarter. Gilbert & Cook Inc. now owns 7,716 shares of the company’s stock valued at $1,432,000 after purchasing an additional 252 shares during the period. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Down 4.4%

Shares of NYSE ABBV opened at $218.14 on Monday. The firm’s 50-day moving average is $222.42 and its 200-day moving average is $201.15. AbbVie Inc. has a 1 year low of $163.81 and a 1 year high of $244.81. The firm has a market capitalization of $385.35 billion, a PE ratio of 103.87, a price-to-earnings-growth ratio of 1.42 and a beta of 0.51. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same quarter last year, the firm earned $3.00 EPS. AbbVie’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is 524.24%.

Insider Activity at AbbVie

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of AbbVie stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the transaction, the executive vice president owned 177,292 shares of the company’s stock, valued at $35,178,278.64. This trade represents a 19.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Nicholas Donoghoe sold 13,295 shares of AbbVie stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the transaction, the executive vice president directly owned 58,247 shares in the company, valued at $11,562,611.97. The trade was a 18.58% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Citigroup reissued a “neutral” rating on shares of AbbVie in a report on Monday, October 13th. Hsbc Global Res cut shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Raymond James Financial reiterated an “outperform” rating and set a $250.00 target price (up previously from $236.00) on shares of AbbVie in a research report on Friday, October 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. Finally, BMO Capital Markets increased their target price on shares of AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a research report on Friday, September 12th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $234.80.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.